Thousands of procurers and QA professionals review ophthalmic and otic formulation manufacturing suppliers every year. The majority look for a GMP certificate, request a certificate of analysis, and move on.
In their minds, this process validates their source of supply. In truth, it is a failed exercise in diligence.
The eye is a direct pathway to the brain and the bloodstream via the circulatory system. It has virtually no defence against contamination.
The anterior chamber of the eye lacks protective mechanisms, such as an acid bath or an enzymatic barrier, to slow the spread of pathogens.
An intentionally administered contaminated eye drop can deliver a disease-causing agent to the most infection-sensitive tissue in the body and cause blindness, systemic sepsis and even death.
Consequently, the traditional due diligence checks for procurement and QA personnel are inadequate for this category.
The concern is not “did the product pass a sterility test?” The concern is “how was sterility designed and engineered in this product?”
The answer to this question requires the assessment and balancing of several benchmarks, including the product quality, the integrity of the manufacturing environment, and the contracts, as well as the technical line separating ophthalmic and otic formulations.
What this guide presents is a system and a series of benchmarks for assessing the sourcing of sterile ophthalmic and otic pharmaceutical products.
Why Ophthalmic & Otic Are a Category Apart
Ophthalmic and otic products comprise the highest-risk tier in pharmaceutical procurement, and this segment of the market is booming.
Knowledge of what makes these products different forms the basis of the following discussion.
The most unforgiving dosage form
Ophthalmic products are at the top of the pharmaceutical risk hierarchy.
For these products, every aspect of the product should be of high quality, and in particular, every container must be completely free of microorganisms and other contaminants at the time of closure.

From a regulatory perspective, we must consider the requirements for injectable products, i.e. sterility, the presence of particulate matter, pH, osmolality, preservative efficacy, and the integrity of the closure system, since the eye has very little protection against contamination.
These aspects are covered in FDA’s guidance and USP’s <771>.[1]
The size of the market is in line with the consequences of failure.
The global market for ophthalmic drugs was approximately USD 31 billion in 2023, and is projected to reach approximately USD 49.4 billion by 2032.[2]
The CAGR is projected at approximately 5.3% ( the page reports inconsistent CAGR figures of 5.1% and 5.2%.
The implied CAGR calculated from the two market values over nine years is approximately 5.3%) during this period.
The use of eye drops continues to dominate the market. From a regional perspective, the fastest-growing market is the Asia-Pacific region.
The market for otic (ear) drugs, while much smaller (approximately USD 1.77 billion in 2024),[3] is projected to grow at a CAGR of 6.45%[3] during the same period to reach approximately USD 2.92 billion in 2032.[3]
Snapshot of the market: Global ophthalmic drugs are projected to grow from approximately USD 31 billion (2023) to approximately USD 49.4 billion (2032) with a CAGR of 5.1% during the forecast period.
Global otic drugs are projected to grow from approximately USD 1.77 billion (2024) to approximately USD 2.92 billion (2032) with a CAGR of 6.45% during the forecast period.
Ophthalmic and otic are related – but not the same
The most expensive misunderstanding in this category is considering ophthalmic and otic products as the same.
They may appear similar as small-volume liquid and semi-solid dosage forms, sometimes manufactured on the same lines, but have different sterility requirements.
All products intended for use in the eye must be sterile and of injectable grade.
Most otic products do not have to be sterile. These products are assessed against non-sterile microbial limits.
A significant exception is products intended for use following a perforated eardrum or post-surgical products.
The application of a non-sterile otic product to a perforated eardrum allows direct access of the pathogen to the middle ear and may result in infection or hearing loss.
A failure to appreciate the distinctions between ophthalmic and otic products may result in inadequate protection of the patient or unnecessarily increase cost and complexity.
We will now detail why this category necessitates a different standard, and why a sterility test, the quality standard most often relied on, is inadequate.
Why ‘It Passed a Sterility Test’ Is Not Enough
A certificate of analysis is not an assurance of a safe supplier.
Understanding this, and what actually guarantees sterility, is essential to effective ophthalmic procurement.
The most important quality assurance principle in ophthalmology is this: you cannot test your way to sterility.

Sterility tests, as described in the United States Pharmacopoeia (USP) chapter <71>, are destructive.
Only a small representative sample of a batch is tested for sterility. A batch of 10,000 units might have only 14 units of that batch tested for sterility.
Statistically, a contaminated batch and a batch with a higher contamination rate can pass this test.
The results of the sterility test are certainly reassuring, but the test results do not prove that every unit in that batch is sterile.
Sterility must be deliberately designed and manufactured into the process.
Validated terminal sterilisation or controlled aseptic processing, verified container-closure integrity, and an effective contamination control strategy are the key elements that ensure a sterile product.
End-product testing, including sterility testing, is done to confirm that the process and controls in place work as intended.
It is not designed to create or provide assurance of a sterile product.
Regulatory Principle: The 2022 revision of EU GMP Annex 1[4] states that a holistic Contamination Control Strategy (CCS) must be in place and that the simulation of an aseptic process (media fills) is a verification activity and not the primary assurance activity.
The primary assurance is designed into the process and verified with the use of barriers and controls.
Testing, in this case, confirms the process and controls in place but not primary assurance.
The practical takeaway for the buyer is that a sterility test or certificate of analysis should not be the sole basis for qualifying a supplier as safe.
Buyers should also be inquiring how the supplier ensures and builds in sterility.
Buyers should have a benchmark to assess the adequacy of the answer.
Summary so far
Products for the eye must be of the highest injectable grade.
Products for the ear do not require injectable grade, only sterility unless used with a perforated eardrum or post-surgery.
A sterility test is assuring but not sufficient. Sterility must be built into a process.
The market is large and rapidly growing. The consequences of errors are irrevocable.
What Happens When the Benchmarks Fail
There are very real consequences to failing to follow current good manufacturing practices in ophthalmic products.
Those consequences include patient death and blindness.
The following case illustrates the kinds of things the quality benchmarks are designed to prevent.

A product ‘intended to be sterile’ that wasn’t
There is a case when Artificial tears manufactured by a company and intended to be sterile were linked in 2023 to an outbreak of an extensively drug-resistant Pseudomonas aeruginosa strain (never seen in the U.S. before).
By May 2023, the CDC reported 81 patient cases across 18 U.S. states, 4 deaths, 14 vision loss cases,[5] and multiple eye removals.
The CDC further stated these incidents were not adverse events from a known artificial tear side effect.
They were manufacturing failures resulting in the product, intended to be sterile, coming into contact with the eye and having no defence against it.
The manufacturing failures behind it
The FDA’s follow-up inspection attributed the catastrophe to the facility’s failure to adequately implement a system to control contamination.
Gaps were identified in the facility’s protocols for prevention of contamination and the testing of microorganisms.
Further, the facility failed to use proper tamper-evident packaging.
The Firm shipped a product without assurance of sterility, thus removing the last line of defence against possible microbial contamination. The firm was placed on FDA Import Alert.

Lessons learned from this incident are broad in scope and apply to all manufacturers and countries of origin.
Failure to ensure product integrity increases the risk of a wider range of reputation losses that encompass the entire supplier base.
Failure of a single manufacturer to meet product integrity requirements destroys trust in the region’s pharmaceutical export and the entire supply chain.
The case is documented and cited here to illustrate the importance of the manufacturing practices described in the subsequent sections of this paper and to provide a clear example of what happens when these practices are not followed.
We have seen the costs in human terms of failing to meet benchmarks; now let’s look at the specific quality standards for products against which good performance is measured.
The Product-Quality Benchmarks to Demand
The core attributes are common across major pharmacopoeias, the specific requirements vary by market.
A serious buyer will insist that any ophthalmic product be tested against those standards and that the tests, specifications and controls be made part of the purchase.
Regardless of the regulatory framework (US FDA, EU GMP, WHO-GMP, etc.), these standards are the same and must be met for any product designed to come into contact with the eye or, for that matter, with the sterile middle ear.
| Quality Attribute | Standard / Basis | What Good Looks Like |
| Sterility | USP Sterility Tests | Validated sterility assurance; every container sterile at fill and closing. Sterility must be built into the process, not tested into the product. |
| Particulate matter | USP (referencing visible/sub-visible particulate chapters) | Injectable-grade particulate limits met; robust visual inspection at 100%. |
| Antimicrobial preservative efficacy | USP Antimicrobial Effectiveness Testing | Preservative effective across the full shelf life; content specified, controlled, and tested. |
| Container-closure integrity (CCI) | USP / stability-supported | Demonstrated microbial-ingress barrier throughout the shelf life and in-use period. |
| pH & osmolality (isotonicity) | USP / pharmacopoeial | Within ocular-tolerable range (pH 6-8; approximately 290-310 mOsm/kg); consistent batch-to-batch. |
| Sterility of the container itself | USP / FDA guidance | Pre-sterilised primary components; tamper-evident seal verified. |
| Impurities, degradation, extractables & leachables | ICH Q3 / FDA guidance | Characterised impurity and extractables and leachables (E&L) profile; leachables below safety-qualified thresholds. |
| Assay, identity, minimum fill | USP / product monograph | Potency within specification; labelled fill delivered in every unit. |
Now that we’ve looked at what the product needs to do, let’s look at what the manufacturing facility needs to show us.
The Sterile-Manufacturing Benchmarks
Since manufacturing techniques and processes inherently build in sterility, a serious buyer should expect verification of the following at a potential supplier’s facility, based on the EU GMP Annex 1 benchmarks, and audit the supplier against them.
Annex 1 (revised 2022) is the most comprehensive and the most widely adopted standard for sterile manufacturing globally, and its principles are referenced by the FDA, WHO, and other major regulators.
| Manufacturing Element | Annex 1 / GMP Benchmark | What to Verify |
| Contamination Control Strategy (CCS) | A single documented, risk-based strategy covering the whole site | A real, current CCS document not a folder of disconnected SOPs. |
| Cleanroom classification | Grades A-D; Grade A (ISO 5) for the critical fill zone; Grade B background | Cleanroom qualification records and continuous Grade A particle-monitoring data. |
| Sterilisation route | Terminal sterilisation preferred; aseptic processing only where unavoidable | A justified, validated choice not aseptic processing by default without documented rationale. |
| Barrier technology | Isolators or Restricted Access Barrier Systems (RABS) preferred to limit human intervention in critical zones | Barrier systems in the fill zone and documented minimisation of interventions. |
| Aseptic process simulation | Media fills at risk-based frequency | Current, passing media fills, with all relevant interventions represented in the simulation. |
| Filtration & aseptic connections | Validated sterilising-grade filtration and sterilised connections | Filter integrity testing records and steam-in-place (SIP) where feasible. |
| Environmental & personnel monitoring | Routine environmental monitoring (EM) across all grades; gowning qualification | Trended EM data with defined limits and out-of-trend (OOT) investigations; personnel monitoring on Grade B exit. |
| Container-closure systems | Pre-sterilised; Blow-Fill-Seal (BFS) where appropriate, with Grade A air protection | Validated container-closure systems (CCS), BFS seal-integrity controls, and a validated cycle. |
Blow-Fill-Seal (BFS) note: BFS technology forms,[6] fills, and seals the container in one automated operation a major advantage for preservative-free ophthalmic formulations.
Aseptic BFS may operate in a Grade C room with Grade A air protection at the fill point; terminally sterilised BFS requires at least Grade D.
Always confirm which approach applies and request the corresponding validation data.
Summary
Sections 4 and 5 cover the two layers of the benchmarking framework: what a product must deliver (USP <71>, <771>, <51>, <1207>, ICH Q3) and what a facility must demonstrate (Annex 1 CCS, cleanroom grades, terminal sterilisation (preferred), barrier technology, media fills, trended EM).
Both layers are required; one without the other is incomplete.
Now that we have looked at manufacturing benchmarks, let’s look at where exactly the sterility requirement applies and the most misunderstood section of this specification.
The Ophthalmic-vs-Otic Line – Get It Exactly Right
The difference between ophthalmic and otic is a discerning detail known by a seasoned buyer.
Getting this detail correct protects patients from potential harm.
The most misunderstood detail in this category is where sterility is required for otic formulations.
Getting this wrong in one direction will fail to adequately protect patients from middle-ear infections or perforation.
Getting this incorrect in the other direction will potentially unnecessarily increase cost for a supplier to produce a non-sterile product.
This detail is often misunderstood because of the various formulations that can be produced.
This can make it seem as though some formulations would necessarily be sterile or non-sterile. This is not always the case.
| Dimension | Ophthalmic (Eye) | Otic (Ear) |
| Sterility required? | Yes, always, without exception. | Usually no, but yes for perforated eardrum or post-surgical use. |
| Standard applied | Injectable-grade standards (USP , ). | Non-sterile microbial limits, unless a sterile indication applies. |
| Preservative efficacy | USP required for multi-dose products; preservative-free formulations are increasingly used for sensitive eyes. | Required for multi-dose products; preservative-free formulations are gaining interest for perforated-eardrum applications. |
| Container-closure integrity | Critical microbial ingress can cause a patient-safety failure. | Critical where sterility is required; important otherwise for product integrity. |
| Key patient risk | Blindness, severe eye infection, and systemic sepsis. | Ototoxicity and middle-ear infection, with severe risks when the eardrum is perforated. |
Convergence trend: Preservative-free, sterile, unit-dose formats are becoming the preferred method of delivery for otic products.
The technology to create these products is evolving from the field of ophthalmology to the field of otology.
Suppliers who can successfully produce these preservative-free, sterile, unit-dose formats are becoming increasingly valuable in both categories.
With both the product and manufacturing benchmarks established, let’s create a practical verification framework based on them.
The Buyer’s Due-Diligence Checklist
Benchmarks only work if the buyer confirms them.
The following checklist changes the technical requirements into actions that can be taken during procurement and auditing.
These actions are to be taken directly at the source, rather than evaluating a PDF copy.
Before the sourcing of any ophthalmic or sterile otic product, verify the following:
| What to Demand / Verify | Why It Matters | Red Flag |
| GMP status for sterile products, verified on the regulator’s public register | Sterile GMP is a distinct, higher standard and is not automatically covered by a general GMP certificate. | GMP certificate that does not explicitly cover sterile manufacturing operations. |
| A current, documented Contamination Control Strategy (CCS) | Annex 1’s central requirement the CCS ensures sterility is managed as a system, not merely through a series of tests. | No CCS, or a box-ticking document that no one at the site actively owns. |
| Sterilisation route and validation data (terminal or aseptic, with rationale) | Defines the sterility-assurance basis for every batch. | “Aseptic by default” with no documented justification or current media-fill data. |
| Recent passing media fills and trended environmental monitoring data | Demonstrates that aseptic control works in practice, not just on paper. | Missing, stale (more than 12 months old), or selectively presented data. |
| Container-closure integrity (CCI) data, supported by stability studies | Demonstrates that the microbial barrier remains effective throughout shelf life and in-use periods, which is critical for preservative-free products. | CCI claimed but not demonstrated with stability data or in accordance with USP . |
| USP preservative efficacy testing (PET) data | For multi-dose products, preservative efficacy throughout shelf life is a patient-safety requirement. | Multi-dose product with no PET data, or data available only at release rather than at the end of shelf life. |
| FDA Form 483 inspection history, warning letters, and import alert status | Past quality failures in sterile manufacturing can indicate significant future quality risks. | Recent sterility-related findings, an active import alert, or unexplained gaps in the inspection history. |
| On-site audit of the sterile fill line and QC laboratory | Documents describe intended practices; the facility demonstrates actual practices. Nothing substitutes for an on-site visit. | Reluctance to allow access to the sterile manufacturing area or QC laboratory during the audit. |
Summary
The due diligence checklist incorporates benchmarks for GMP sterile manufacture.
These include verification of the real CCS, the sterilisation route and validation, current media fills and EM data, CCI stability data, preservative efficacy testing and inspection history.
Confirm all on-site. Suppliers who welcome the due diligence process indicate quality. Suppliers resisting the due diligence process signal risk.
What a Quality-Assured Ophthalmic & Otic Partner Looks Like
The checklist above outlines what should be considered the bare minimum standard for a manufacturer who takes sterility seriously.
A genuine quality partner in this category is not defined by the length of their product catalogue or the age of their GMP certificate.

A genuine quality partner is defined by the depth and transparency of their manufacturing quality systems. These include but are not limited to:
Actiza Pharmaceutical manufactures ophthalmic and otic formulations and is WHO-GMP certified for finished-dose manufacturing.
This includes the quality systems and sterile-capable infrastructure needed for manufacturing and the required documentation transparency.
The quality-assurance credentials and product range are available on the Quality Assurance and Certifications pages.
For procurement and quality teams sourcing this category, the next best step is either a specification review or an on-site audit of the sterile line, and we welcome both.
FAQ
Q1. Do both ophthalmic and otic products need to be sterile?
Ocular (ophthalmic) products, especially those for topical use, require sterility, without exception. As mentioned earlier, the eye provides limited protection against an insult, and its consequences are often irreversible.
Ocular (ophthalmic) products, especially those for topical use, require sterility, without exception. As mentioned earlier, the eye provides limited protection against an insult, and its consequences are often irreversible.
Ear products are less stringent, and the vast majority of them are manufactured in a non-sterile state.
However, an otic product indicated for use with a perforated eardrum, or in post-surgical care, must be prepared sterile, since a perforated eardrum provides a direct path to the middle ear.
Treating all otic products as non-sterile is an under-specification; on the other hand, treating all otic products as sterile is an over-specification error. Specification of requirements must be correct prior to considering sterility.
Q2. What quality standards apply to ophthalmic manufacturing?
Some key standards for ophthalmic manufacturing are USP <1207> (container closure integrity), USP <51> (antimicrobial preservative efficacy), ICH Q3 (impurities, cleaning validation, extractables/leachables, SGL, and the manufacturing environment), USP <71> (sterility testing), and <771> (ophthalmic preparations, covering particulates, sterility, pH, osmolality, container closures).
EU GMP Annex 1 (2022), which aligns the global standard of practice for sterile manufacturing, includes the Contamination Control Strategy, classification (Grades A-D) of cleanrooms, and the frequency of media fills. The core attributes are common across major pharmacopoeias, the specific requirements vary by market.
Q3. Why is a passing sterility test not enough for eye drops?
Sterility testing, as outlined in USP <71>, is inherently restricted by sample size. A batch of thousands of units has only a small number of units tested, and the test is destructive; those units cannot be released.
A batch that is contaminated can, statistically, pass a limited sterility test. This is why regulators and the pharmacopoeias have stated that the manufacturing system has to assure sterility through a validated terminal sterilisation or aseptic processing, supported by container-closure integrity and a true contamination control strategy.
Testing end-products does not guarantee or create sterility. A buyer who accepts an end-product test without understanding or evaluating the manufacturing system accepts risk.
Q4. What should a buyer verify before sourcing ophthalmic or otic products?
Before sourcing, evaluate:
(1) evidence of a GMP status (on the public register of the relevant regulator) for sterile manufacturing.
(2) the latest Contamination Control Strategy.
(3) the rationale for, and validation of the sterilization process (terminal or aseptic).
(4) recent media fills and trends in environmental monitoring.
(5) container-closure integrity and testing supported by stability studies.
(6) preservative efficacy testing for multi-dose products (USP <51>).
(7) the FDA inspection history and 483 observations and warning letters.
(8) an on-site audit of the sterile fill and QC lab. Documents explain a manufacturer’s intent; on-site audits show what the manufacturer does.
Q5. Why are preservative-free eye and ear drops growing, and what do they demand of manufacturing?
Preservative-free formulations are becoming increasingly popular because many patients who require chronic eye drop therapy (such as for glaucoma or dry eye) may develop a condition known as ocular surface disease (OSD) due to cumulative toxicity from preservatives.
Eliminating the preservative from the formulation eliminates the risk of OSD, but also removes the product’s last line of defence against microbial contamination. This means the manufacturing system must provide absolute sterility assurance (validated sterile fill, demonstrated container-closure integrity, and a unit-dose or special type of multi-dose container system), and Blow-Fill-Seal technology is widely used for this.
For ear drops, if a patient has a perforated eardrum, preservatives can also put them at risk for ototoxicity; therefore, the formulations for these patients should also be sterile and preservative-free.
Conclusion
There is zero tolerance for subpar quality for ophthalmic and sterile otic products.
A product that is not totally sterile can potentially take a patient’s life, and the evidence shows that when quality benchmarks slip, the outcomes are disastrous.
The negative effects ripple out to the entire supplier base. The protection is not a certificate. It is a system.
This system involves Built-in Sterility, as well as a genuine contamination control strategy and preservative efficacy demonstrated through the shelf life of the product, and most importantly, using the proper specification to distinguish between sterile and non-sterile.
Global buyers who understand and verify these benchmarks can feel secure sourcing these products.
When a potential partner has systems in place to meet these requirements and provides little to no obstruction during the verification process, it is a strong indicator of the overall quality of the potential partner.
- https://www.fda.gov/media/172937/download
- https://gminsights.com/industry-analysis/ophthalmology-drugs-market/market-size
- https://databridgemarketresearch.com/reports/global-otic-drugs-market
- https://intuitionlabs.ai/articles/eu-gmp-annex-1-contamination-control-strategy
- https://glance.eyesoneyecare.com/stories/2023-05-19/cdc-reports-new-fatalities-vision-loss-in-eye-drop-recall/
- https://www.gxpcellators.com/eu-gmp-certification-requirements-sterile-manufacturing/
